ES2452691T5 - Uso de ciclesonida para el tratamiento de enfermedades respiratorias - Google Patents

Uso de ciclesonida para el tratamiento de enfermedades respiratorias Download PDF

Info

Publication number
ES2452691T5
ES2452691T5 ES04766791T ES04766791T ES2452691T5 ES 2452691 T5 ES2452691 T5 ES 2452691T5 ES 04766791 T ES04766791 T ES 04766791T ES 04766791 T ES04766791 T ES 04766791T ES 2452691 T5 ES2452691 T5 ES 2452691T5
Authority
ES
Spain
Prior art keywords
ciclesonide
use according
dione
dose
child
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04766791T
Other languages
English (en)
Spanish (es)
Other versions
ES2452691T3 (es
Inventor
Thomas Bethke
Renate Engelstaetter
Wilhelm Wurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Covis Pharma GmbH
Original Assignee
Covis Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34312429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2452691(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Covis Pharma GmbH filed Critical Covis Pharma GmbH
Application granted granted Critical
Publication of ES2452691T3 publication Critical patent/ES2452691T3/es
Publication of ES2452691T5 publication Critical patent/ES2452691T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
ES04766791T 2003-09-16 2004-09-15 Uso de ciclesonida para el tratamiento de enfermedades respiratorias Expired - Lifetime ES2452691T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50298403P 2003-09-16 2003-09-16
US502984P 2003-09-16
PCT/EP2004/052172 WO2005025578A1 (en) 2003-09-16 2004-09-15 Use of ciclesonide for the treatment of respiratory diseases

Publications (2)

Publication Number Publication Date
ES2452691T3 ES2452691T3 (es) 2014-04-02
ES2452691T5 true ES2452691T5 (es) 2022-09-14

Family

ID=34312429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04766791T Expired - Lifetime ES2452691T5 (es) 2003-09-16 2004-09-15 Uso de ciclesonida para el tratamiento de enfermedades respiratorias

Country Status (11)

Country Link
US (4) US8371292B2 (https=)
EP (1) EP1670482B2 (https=)
JP (2) JP5618452B2 (https=)
AU (1) AU2004271744B2 (https=)
CA (1) CA2538419C (https=)
DK (1) DK1670482T4 (https=)
ES (1) ES2452691T5 (https=)
HR (1) HRP20140257T4 (https=)
PL (1) PL1670482T5 (https=)
PT (1) PT1670482E (https=)
WO (1) WO2005025578A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2312844T3 (es) * 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
AU2004271744B2 (en) 2003-09-16 2010-07-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
WO2005082413A2 (en) * 2004-02-27 2005-09-09 Altana Pharma Ag Ciclesonide and glycopyrronium combination
EP1740188A1 (en) * 2004-04-20 2007-01-10 Altana Pharma AG Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
JP2009526068A (ja) * 2006-02-08 2009-07-16 シコール インコーポレイティド シクレソニド結晶形
US20100210611A1 (en) * 2007-10-25 2010-08-19 Roch Thibert Combination therapy
AU2010221972B2 (en) * 2009-03-09 2012-07-05 Mikasa Seiyaku Co., Ltd. Steroid compound
US11007150B2 (en) * 2011-08-18 2021-05-18 Covis Pharma Gmbh Pharmaceutical aerosol product for administration by oral or nasal inhalation
US10925964B2 (en) 2012-12-21 2021-02-23 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical formulation comprising ciclesonide
HRP20181980T1 (hr) 2012-12-21 2019-01-25 Boehringer Ingelheim Vetmedica Gmbh Ciklezonid za liječenje dišnih puteva kod konja
MX370430B (es) 2014-06-18 2019-12-13 Boehringer Ingelheim Vetmedica Gmbh Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos.
WO2017161442A1 (en) * 2016-03-24 2017-09-28 Services Medicaux Arnold Et Joan Zidulka Inc. Device and method of delivering particles in the upper respiratory tract
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE9716T1 (de) * 1980-02-27 1984-10-15 Tate & Lyle Public Limited Company Kristalline glukose und verfahren zu deren herstellung.
US4816445A (en) * 1984-06-21 1989-03-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Crystalline alpha-maltose
JP2518646B2 (ja) * 1987-05-29 1996-07-24 株式会社 林原生物化学研究所 マルト−ス粉末の製造方法
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE407028T1 (de) 1989-05-31 1994-03-17 Fisons Plc Medikament und Inhalationsvorrichtung dafür.
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US6536427B2 (en) * 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
AU654813B2 (en) 1990-03-23 1994-11-24 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US5434304A (en) * 1990-09-26 1995-07-18 Aktiebolaget Astra Process for preparing formoterol and related compounds
JP2769925B2 (ja) 1990-10-18 1998-06-25 ミネソタ マイニング アンド マニュファクチャリング カンパニー ベクロメタゾン１７，２１ジプロピオネートを含んで成るエアロゾル製剤
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6866839B2 (en) * 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
ZA924164B (en) * 1991-06-10 1993-02-24 Schering Corp Non-chlorofluorocarbon aerosol formulations
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
GB9213874D0 (en) 1992-06-30 1992-08-12 Fisons Plc Process to novel medicament form
GB9306703D0 (en) 1993-03-31 1993-05-26 Fisons Plc Inhalation device
UA45311C2 (uk) 1993-04-02 2002-04-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх 16<font face="Symbol">a</font>,17-ЦИКЛОГЕКСИЛМЕТИЛЕНДІОКСИ-11<font face="Symbol">b</font>,21-ДИГІДРОКСИПРЕГНА-1,4-ДІЄН-3,20-ДІОН, СПОСІБ ЙОГО ОДЕРЖАННЯ, ЛІКАРСЬКИЙ ЗАСІБ
US5476411A (en) 1993-07-16 1995-12-19 Henkel Corporation Aqueous composition for wet sanding of dried paint, plastics, and the like
IL111194A (en) 1993-10-08 1998-02-08 Fisons Plc Process for the production of medicament formulations
DE4434629C1 (de) * 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
DE19541689A1 (de) 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
MX9707864A (es) 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida por salmeterol.
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
DE69635048T2 (de) * 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
EP0852498A1 (en) * 1995-09-26 1998-07-15 Takeda Chemical Industries, Ltd. Phosphorylamides, their preparation and use
DE19635498A1 (de) 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
US6380222B2 (en) * 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
FR2754712B1 (fr) * 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US20020111495A1 (en) * 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
GB2329939A (en) * 1997-06-26 1999-04-07 Glaxo Group Ltd Self-lubricating valve stem for aerosol containers
US6470894B2 (en) 1997-09-19 2002-10-29 Thione International, Inc. Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
AU1507199A (en) * 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives
SE9801368D0 (sv) 1998-04-20 1998-04-20 Astra Ab New use
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6264923B1 (en) * 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
JP4570251B2 (ja) * 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
EE04677B1 (et) 1998-09-23 2006-08-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahdropridoeetrid, nende kasutamine ja ravim
AU756852B2 (en) * 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6397838B1 (en) * 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
US6124268A (en) * 1999-02-17 2000-09-26 Natreon Inc. Natural antioxidant compositions, method for obtaining same and cosmetic, pharmaceutical and nutritional formulations thereof
AU777169B2 (en) * 1999-04-23 2004-10-07 Battelle Memorial Institute High mass transfer electrosprayer
JP4677102B2 (ja) * 1999-04-23 2011-04-27 バテル・メモリアル・インスティテュート エーロゾル給送装置及びエーロゾル小滴を給送する方法
JP2001048807A (ja) 1999-08-04 2001-02-20 Wakamoto Pharmaceut Co Ltd 難溶性薬物を水に溶解してなる製剤
DE19947234A1 (de) 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
AR026072A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0009607D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
FI20002177A0 (fi) 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
CA2425035A1 (en) 2000-10-09 2002-04-18 3M Innovative Properties Company Medicinal aerosol formulations
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20020183292A1 (en) * 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
AU2002227123A1 (en) * 2000-11-07 2002-05-21 Merck And Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist
AU2002222304B2 (en) * 2000-12-22 2004-03-18 Glaxo Group Limited Metered dose inhaler for salmeterol xinafoate
WO2003006310A1 (fr) 2001-07-13 2003-01-23 Tfe Techniques Et Fabrications Electroniques Dispositif destine a indiquer acoustiquement a un plongeur equipe d'un scaphandre la pression de gaz de respiration dans le reservoir et/ou la pression hydrostatique
JP2005508220A (ja) * 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
EP1453743B1 (en) 2001-11-17 2008-07-23 Aventis Pharma Limited Pharmaceutical product and method with an adsorbent
EP1453493A2 (en) * 2001-11-19 2004-09-08 ALTANA Pharma AG Reversible proton pump inhibitors for the treatment of airway disorders
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
BRPI0312377A8 (pt) * 2002-07-02 2015-12-15 Altana Pharma Ag Suspensão aquosa estéril contendo ciclesonida
ES2312844T3 (es) 2002-12-12 2009-03-01 Nycomed Gmbh Medicamento de combinacion de r, r-formoterol y ciclesonida.
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
AU2004271744B2 (en) 2003-09-16 2010-07-29 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases

Also Published As

Publication number Publication date
US20130143849A1 (en) 2013-06-06
WO2005025578A1 (en) 2005-03-24
HRP20140257T1 (hr) 2014-04-25
CA2538419A1 (en) 2005-03-24
EP1670482B2 (en) 2022-06-29
PT1670482E (pt) 2014-03-12
EP1670482A1 (en) 2006-06-21
AU2004271744B2 (en) 2010-07-29
DK1670482T3 (en) 2014-03-17
AU2004271744A1 (en) 2005-03-24
JP5618452B2 (ja) 2014-11-05
JP2012197306A (ja) 2012-10-18
PL1670482T5 (pl) 2022-10-03
US8371292B2 (en) 2013-02-12
US20190290661A1 (en) 2019-09-26
US20220241297A1 (en) 2022-08-04
US20070025923A1 (en) 2007-02-01
DK1670482T4 (da) 2022-08-22
CA2538419C (en) 2012-07-03
JP2007505829A (ja) 2007-03-15
HRP20140257T4 (hr) 2022-11-25
ES2452691T3 (es) 2014-04-02
PL1670482T3 (pl) 2014-05-30
EP1670482B1 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
US20220241297A1 (en) Use of ciclesonide for the treatment of respiratory diseases
US20060293293A1 (en) Salmeterol and ciclesonide combination
ES2238334T3 (es) Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
ES2774391T3 (es) Composiciones, métodos y sistemas para la administración respiratoria de dos o más agentes activos
ES2468835T3 (es) Terapia combinada para EPOC
HU226694B1 (en) Medicinal aerosol products containing ciclesonide
ITRM20000491A1 (it) Formulazione farmaceutica di propionato di fluticasone.
ES2487626T3 (es) Formulaciones farmacéuticas en aerosol de formoterol y dipropionato de beclometasona
US9402854B2 (en) Pharmaceutical composition
EP1720577A2 (en) Ciclesonide and glycopyrronium combination
AU2005235384B2 (en) Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
AU2004246819A1 (en) Formoterol and ciclesonide combination
BR102012027127A2 (pt) Composição contida em um inalador farmacêutico pressurizado com medidores de dosagem
HK1167817B (en) Pharmaceutical aerosol formulations of formoterol and beclometasone dipropionate
BR102012008322B1 (pt) formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa